• INDUSTRIES
  • SERVICES
  • FDA REQUIREMENTS
  • NEWS & MEDIA
  • BLOG
  • ABOUT
  • CONTACT
  • SHOP

* You are viewing Posts Tagged ‘cancer’

Prop 65 Press Releases Are Blood in the Water for California Plaintiff’s Attorneys

admin April 30, 2012 Cosmetics, Law & Regulatory No Comments

Tags: birth defects, blood, California, California Department of Toxic Substances Control, California Office of Environmental Health Hazard Assessment, cancer, cosmetics, Dibutyl Phthalate, DTSC, FDA Warning Letter, Formaldehyde, JAWS, labeling, nail polish, OEHHA, prop 65, Proposition 65, sharks, Toluene

Prop 65 Press Releases Are Blood in the Water

Cue the soundtrack from Jaws.

Earlier this month, the California Department of Toxic Substances Control (DTSC) issued a press release alleging that several nail polish manufacturers failed to declare the presence of potentially dangerous cosmetic ingredients, Toluene, Dibutyl Phthalate (DBP) and Formaldehyde. DTSC based its allegations on initial testing of 25 different cosmetic brands, chosen at random. The investigation also revealed that many of the brands failed to declare these ingredients even though their labeling explicitly stated they were free of these chemicals.

California authorities … READ MORE

Google+FacebookTwitterRedditStumbleUponPinterestLinkedInShare

Just Like Fake Avastin, Pending Counterfeit Drug Legislation Doesn’t Do Anything Either

admin April 25, 2012 Drugs, Imports, Law & Regulatory No Comments

Tags: 18 U.S.C. § 2320, Avastin, cancer, counterfeit, Counterfeit Drug Penalty Enhancement Act of 2011, distribution, drugs, fake, IP, logo, penalties, Senator Bennett, treatment

Avastin Fake Drug Legislation

In February 2012, news of fake Avastin in the United States hit the news wires.  Cancer patients were being administered water while under the impression that it was the actual cancer treatment drug, Avastin.  People were outraged.  Weeks later, another shipment of the counterfeit drug was discovered in the United States.  “What’s being done about this?” was the outcry from the press.  Shortly thereafter, the Senate passed the Counterfeit Drug Penalty Enhancement Act of 2011,1 a bill that had been sitting in committee … READ MORE

Google+FacebookTwitterRedditStumbleUponPinterestLinkedInShare


  • Get our blog in your inbox


     



  • Topics

    • China (31)
    • Company News (73)
    • Cosmetics (30)
    • Dietary Supplements (12)
    • Drugs (17)
    • Events (16)
    • Food (101)
    • Food Safety Modernization Act (46)
    • Humor (10)
    • Imports (55)
    • Law & Regulatory (122)
    • Medical Devices (15)
    • Uncategorized (4)
    • USDA (3)
  • Archives

-->

© 2013 FDAImports.com, LLC. All Rights Reserved.
810 Landmark Drive, Suite 126  |  Glen Burnie, Maryland 21061  |  ph: (410) 220-2800  |  fx: (443) 583-1464
FDAImports.com, LLC is a private FDA regulatory consulting firm and is not the FDA

Privacy Policy  |  Disclaimer  |  Sitemap  |  Glossary  |  Choose Your Language